Adaptin Bio (APTN) Return on Capital Employed (2024 - 2026)

Adaptin Bio's Return on Capital Employed history runs 3 years deep, the most recent figure standing at 75.8% for Q1 2026.

• In Q1 2026, Return on Capital Employed rose 35127.0% year-over-year to 75.8%; the TTM figure through Mar 2026 stood at 75.8% (up 35127.0% YoY), while the FY2025 annual figure was 64.62%, up 4908.0% from the prior year.
• Return on Capital Employed came in at 75.8% for Q1 2026 at Adaptin Bio, down from 82.89% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 890.69% in Q3 2024 to a low of 275.47% in Q1 2025.
• A 3-year average of 206.52% and a median of 79.34% in 2025 frame the typical range for Return on Capital Employed.
• Across the five-year window, Return on Capital Employed slumped 73955 bps in 2025 and soared 35127 bps in 2026, its largest moves.
• Adaptin Bio's Return on Capital Employed stood at 15.54% in 2024, then surged by 433 bps to 82.89% in 2025, then retreated by 9 bps to 75.8% in 2026.
• According to Business Quant data, Return on Capital Employed over the past three periods registered 75.8%, 82.89%, and 489.5% for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison